I have had my doubts about the relationship betwee
Post# of 148176
(Total Views: 795)
Posted On: 08/01/2020 10:41:25 AM
I have had my doubts about the relationship between NP and BP. Not sure what has transpired but I have "felt" NP a bit cold towards BP. In last conference call he mentioned that "we don't count on Dr. Patterson paper" or something similar. Don't remember the exact words.
Listening to Dr. Patterson interview yesterday it is obvious that he is fully in our side and remains the best Leronlimab advocate. So, I am not sure now that something has gone wrong as Dr. Paterson is talking as he was and is the biggest fan of CytyDyn.
His paper is coming !!!!! Below a transcript (from Dr. Yo's interview) where he explains what is going on:
What is going on with paper: Again I, I’m frustrated by the Journal it up the COVID endemic forcing people to publish preprints; because people who don’t understand the publication process know that it’s a relatively long process, is obvious accelerated in COVID and, and clearly you know, there was, there is several issues, I mean the main being no controls, right? and you know, these patients beyond critical and we are blessed that hum … some of the other coauthors and myself had great collaborators who stepped up the plate and said: listen I got some critical controls that haven’t been treated and let’s ad add those to the paper.
and then, you know, by the time we add those we had day 14th data which made everything even more powerful like I said this inverse correlation between CD8s coming back up and plasma viral load going down, absolutely critical, now people are coming out in reverse saying that is the CD8 deficiency ah, or the recovery of the CD8s ahmm that is eventually, you know, going to eliminate a virally infected cells. So then, we included CD 14th day and then, of course, it was outcomes: you know all 11 patients had incredible immunologic response the outcomes were good for this particular population, 8 out of eleven, or 7 out of 11 were transplant patients on top of everything else .. ah I just had not been addressed … So in fact, I checked on it today and it's, it's in process I think they are probably close to a decision, and then the journals when there is a decision will get it out in e-pub relatively quickly. But if you talk about the time from submission to going out in e-Pub in 3 months I mean, under normal circumstances, we would be popping the champagne bottle in how fast that is, right ??? some publications normally take 6, 12 months from the time they are actually submitted to the time they are out in print. so you know, I get the frustration, I’m just a frustrated at the pace, but you know what ? after publishing 150 papers, nothing, this is business as usual. Are the political things going behind the scenes? possibly ahh. But, in the day is gonna come out; I mean, the bottom line is: you don’t write a great paper and doesn’t get out anywhere is only matter of which journal gets it out there … at the end of the day, it does not matter, right??? if it is in a top tier Journal it's fine but it doesn't have to be, you know, solely New England Journal, Lancet, Nature, Science, you know, I published in all those before and yes, is a great honor but you know what ? they accept one in 100 papers so … yeah there’s other papers on Leronlimab that have undergone the same fate, so, we are in the same boat and I think the recurring theme is: lack of control patients and, obviously, that is going to come in the clinical trials and certainly in the IND’s we didn’t have controls, we didn’t have placebo controls, we went out and got them from our obviously some great collaborators of ours which made the trial much more than just, you know, just, looking at Leronlimab, we had to look at what was going on and repeat the entire assays that we did on the treated patients on the controls, so you can imagine the study size actually double, you know, in the course of, this being evaluated, so again, yeah there’s every reason in the world why, you know, it’s taking this long, but like I said, with, after 150 publications there is nothing that is unusual about this in the least
I can't wait to see the final paper, and more so, the "market" and scientific community reaction to it.
Listening to Dr. Patterson interview yesterday it is obvious that he is fully in our side and remains the best Leronlimab advocate. So, I am not sure now that something has gone wrong as Dr. Paterson is talking as he was and is the biggest fan of CytyDyn.
His paper is coming !!!!! Below a transcript (from Dr. Yo's interview) where he explains what is going on:
What is going on with paper: Again I, I’m frustrated by the Journal it up the COVID endemic forcing people to publish preprints; because people who don’t understand the publication process know that it’s a relatively long process, is obvious accelerated in COVID and, and clearly you know, there was, there is several issues, I mean the main being no controls, right? and you know, these patients beyond critical and we are blessed that hum … some of the other coauthors and myself had great collaborators who stepped up the plate and said: listen I got some critical controls that haven’t been treated and let’s ad add those to the paper.
and then, you know, by the time we add those we had day 14th data which made everything even more powerful like I said this inverse correlation between CD8s coming back up and plasma viral load going down, absolutely critical, now people are coming out in reverse saying that is the CD8 deficiency ah, or the recovery of the CD8s ahmm that is eventually, you know, going to eliminate a virally infected cells. So then, we included CD 14th day and then, of course, it was outcomes: you know all 11 patients had incredible immunologic response the outcomes were good for this particular population, 8 out of eleven, or 7 out of 11 were transplant patients on top of everything else .. ah I just had not been addressed … So in fact, I checked on it today and it's, it's in process I think they are probably close to a decision, and then the journals when there is a decision will get it out in e-pub relatively quickly. But if you talk about the time from submission to going out in e-Pub in 3 months I mean, under normal circumstances, we would be popping the champagne bottle in how fast that is, right ??? some publications normally take 6, 12 months from the time they are actually submitted to the time they are out in print. so you know, I get the frustration, I’m just a frustrated at the pace, but you know what ? after publishing 150 papers, nothing, this is business as usual. Are the political things going behind the scenes? possibly ahh. But, in the day is gonna come out; I mean, the bottom line is: you don’t write a great paper and doesn’t get out anywhere is only matter of which journal gets it out there … at the end of the day, it does not matter, right??? if it is in a top tier Journal it's fine but it doesn't have to be, you know, solely New England Journal, Lancet, Nature, Science, you know, I published in all those before and yes, is a great honor but you know what ? they accept one in 100 papers so … yeah there’s other papers on Leronlimab that have undergone the same fate, so, we are in the same boat and I think the recurring theme is: lack of control patients and, obviously, that is going to come in the clinical trials and certainly in the IND’s we didn’t have controls, we didn’t have placebo controls, we went out and got them from our obviously some great collaborators of ours which made the trial much more than just, you know, just, looking at Leronlimab, we had to look at what was going on and repeat the entire assays that we did on the treated patients on the controls, so you can imagine the study size actually double, you know, in the course of, this being evaluated, so again, yeah there’s every reason in the world why, you know, it’s taking this long, but like I said, with, after 150 publications there is nothing that is unusual about this in the least
I can't wait to see the final paper, and more so, the "market" and scientific community reaction to it.
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼